Most women with ovarian cancer are diagnosed with the most advanced form of the disease. Less than a third of those diagnosed with the disease survive five years later. As the third most common type of gynecological cancer, it led to more than 200,000 reported deaths globally in 2020 alone, according to a recent study.
Another major PBM will cut AbbVie’s Humira from its largest commercial formularies
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
August 27, 2024